54.27 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||54.16 x 1100|
|Ask||54.27 x 800|
|Day's Range||53.81 - 54.74|
|52 Week Range||29.01 - 58.93|
|Beta (3Y Monthly)||1.05|
|PE Ratio (TTM)||26.60|
|Earnings Date||Feb 19, 2019 - Feb 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||47.75|
Anika Therapeutics, Inc. , a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today announced that it will host an Analyst and Investor Day on Wednesday, September 18, 2019 from 9:00 a.m.
Anika Therapeutics, Inc. , a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today announced that Joseph Darling, President and Chief Executive Officer, and Sylvia Cheung, Chief Financial Officer, will participate in a fireside chat at the 2019 Morgan Stanley Global Healthcare Conference on Tuesday, September ...
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
Anika Therapeutics, Inc. (ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the successful completion of the first human surgical procedure with its injectable HA-based bone repair therapy for the treatment of bone voids and other bone defects of the skeletal system caused by trauma or age-related degeneration. The case was performed by Dr. John J. Tierney, an orthopedic surgeon at the New England Baptist Hospital and President of the Greater Boston Orthopedic Center. Approximately 900,000 people require treatment for bone voids and other bone defects of the knee, which cause pain and impaired function that can lead to the need for total joint replacement therapy.
Anika Therapeutics received an upgrade to 'Buy' on Monday from TheStreet.com's quantitative service which comes on the heels of its technical breakout last week. In this daily bar chart of ANIK, below, we can see a year-long base pattern with an upside gap/breakout. The On-Balance-Volume (OBV) line turned up to a new high to confirm the buying and so did the Moving Average Convergence Divergence (MACD) oscillator.
Here are four stocks to watch, three of which are moving on strong earnings reports. Anika Therapeutics Inc. (ANIK) popped $11.78, or 29%, to $52.60 on Thursday on 1.3 million shares traded, or about eight times its average volume. The breakaway gap, and continued runup, broke the stock through several layers of lateral resistance, with the next target at the $61 level last reached in early 2018.
Here are four stocks to watch, three of them moving on strong earnings: Anika Therapeutics, Inc . (NASDAQ: ANIK ) popped $11.78, or 28.8%, to $52.60 on Thursday on 1.3 million shares, or about 8x its average ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 25) Akero Therapeutics Inc (NASDAQ: AKRO ) Anika Therapeutics ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 24) Acasti Pharma Inc (NASDAQ: ACST ) Cardiovascular Systems ...
Anika (ANIK) delivered earnings and revenue surprises of 59.52% and 6.69%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
On Anika Therapeutics' (ANIK) second-quarter earnings call, investor focus will be on its progress with the U.S. approval of its orthopedic product Cingal.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam (ALNY) announces new results from the Global Open-Label Extension study of Onpattro at the 2019 Peripheral Nerve Society (PNS) Annual Meeting.
AMAG Pharmaceuticals (AMAG) announces that the FDA has approved Vyleesi to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.